← Back to Search

Cancer Vaccine

ASKG915 for Solid Tumors

Phase 1
Recruiting
Research Sponsored by AskGene Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years from date of treatment start until data cut-off
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug to see if it's safe & effective against cancer in people with advanced tumors.

Who is the study for?
This trial is for adults with advanced solid tumors that haven't responded to standard treatments or have no standard options left. They should be relatively stable (ECOG ≤ 2), expected to live at least 3 more months, and meet specific lab test criteria. People can't join if they've had recent antitumor therapy, live vaccines, autoimmune diseases, problematic fluid buildup needing drainage, are pregnant/breastfeeding/planning pregnancy during the study period, have brain metastases or serious heart/stroke issues.
What is being tested?
The trial is testing ASKG915's safety and how it affects the body in patients with certain advanced solid tumors. It's an early-phase study where researchers gradually increase doses to find a safe amount while monitoring how participants' bodies process the drug.
What are the potential side effects?
Since this is a Phase 1 dose escalation study of ASKG915 focusing on safety and tolerability, specific side effects aren't listed yet but may include typical reactions like nausea, fatigue, allergic responses or other symptoms depending on how the drug interacts with different tumor types.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years from date of treatment start until data cut-off
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years from date of treatment start until data cut-off for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse events(AEs)
Dose limiting toxicities (DLTs)
Secondary study objectives
Area under the concentration time curve (AUC)
Evaluation of immunogenicity
Maximum plasma concentration (Cmax)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ASKG915Experimental Treatment1 Intervention
Single or multiple ascending dose of ASKG915.

Find a Location

Who is running the clinical trial?

AskGene Pharma, Inc.Lead Sponsor
6 Previous Clinical Trials
1,055 Total Patients Enrolled
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry Sponsor
14 Previous Clinical Trials
2,521 Total Patients Enrolled
Barbara Hickingbottom, MDStudy DirectorAsk-Gene Pharma, Inc.
6 Previous Clinical Trials
534 Total Patients Enrolled

Media Library

ASKG915 (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05867420 — Phase 1
Solid Tumors Research Study Groups: ASKG915
Solid Tumors Clinical Trial 2023: ASKG915 Highlights & Side Effects. Trial Name: NCT05867420 — Phase 1
ASKG915 (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05867420 — Phase 1
~45 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top